tetano
Editor, Senior Moderator
Sens Actuators B Chem
. 2023 Mar 15;379:133245.
doi: 10.1016/j.snb.2022.133245. Epub 2022 Dec 26.
A colorimetric lateral flow immunoassay based on oriented antibody immobilization for sensitive detection of SARS-CoV-2
Ae Sol Lee[SUP] 1 [/SUP], Su Min Kim[SUP] 1 [/SUP], Kyeong Rok Kim[SUP] 1 [/SUP], Chulmin Park[SUP] 2 [/SUP], Dong-Gun Lee[SUP] 2 3 [/SUP], Hye Ryoung Heo[SUP] 4 [/SUP], Hyung Joon Cha[SUP] 5 [/SUP], Chang Sup Kim[SUP] 1 6 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The high human-to-human transmission and rapid evolution of SARS-CoV-2 have resulted in a worldwide pandemic. To contain SARS-CoV-2, it is essential to efficiently control the transmission of the virus through the early diagnosis of infected individuals, including asymptomatic people. Therefore, a rapid and accurate assay is vital for the early diagnosis of SARS-CoV-2 in suspected individuals. In this study, we developed a colorimetric lateral flow immunoassay (LFIA) in which a CBP31-BC linker was used to immobilize antibodies on a cellulose membrane in an oriented manner. The developed LFIA enabled sensitive detection of cultured SARS-CoV-2 in 15 min with a detection limit of 5 × 10[SUP]4[/SUP] copies/mL. The clinical performance of the LFIA for detecting SARS-CoV-2 was evaluated using 19 clinical samples validated by reverse transcription-polymerase chain reaction (RT-PCR). The LFIA detected all the positive and negative samples accurately, corresponding to 100% accuracy. Importantly, patient samples with low viral loads were accurately identified. Thus, the proposed method can provide a useful platform for rapid and accurate point-of-care testing of SARS-CoV-2 in infected individuals to efficiently control the COVID-19 pandemic.
Keywords: Antibody; COVID-19; Lateral flow immunoassay; Orientation; SARS-CoV-2; Sensitive.
. 2023 Mar 15;379:133245.
doi: 10.1016/j.snb.2022.133245. Epub 2022 Dec 26.
A colorimetric lateral flow immunoassay based on oriented antibody immobilization for sensitive detection of SARS-CoV-2
Ae Sol Lee[SUP] 1 [/SUP], Su Min Kim[SUP] 1 [/SUP], Kyeong Rok Kim[SUP] 1 [/SUP], Chulmin Park[SUP] 2 [/SUP], Dong-Gun Lee[SUP] 2 3 [/SUP], Hye Ryoung Heo[SUP] 4 [/SUP], Hyung Joon Cha[SUP] 5 [/SUP], Chang Sup Kim[SUP] 1 6 [/SUP]
Affiliations
- PMID: 36589904
- PMCID: PMC9791791
- DOI: 10.1016/j.snb.2022.133245
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The high human-to-human transmission and rapid evolution of SARS-CoV-2 have resulted in a worldwide pandemic. To contain SARS-CoV-2, it is essential to efficiently control the transmission of the virus through the early diagnosis of infected individuals, including asymptomatic people. Therefore, a rapid and accurate assay is vital for the early diagnosis of SARS-CoV-2 in suspected individuals. In this study, we developed a colorimetric lateral flow immunoassay (LFIA) in which a CBP31-BC linker was used to immobilize antibodies on a cellulose membrane in an oriented manner. The developed LFIA enabled sensitive detection of cultured SARS-CoV-2 in 15 min with a detection limit of 5 × 10[SUP]4[/SUP] copies/mL. The clinical performance of the LFIA for detecting SARS-CoV-2 was evaluated using 19 clinical samples validated by reverse transcription-polymerase chain reaction (RT-PCR). The LFIA detected all the positive and negative samples accurately, corresponding to 100% accuracy. Importantly, patient samples with low viral loads were accurately identified. Thus, the proposed method can provide a useful platform for rapid and accurate point-of-care testing of SARS-CoV-2 in infected individuals to efficiently control the COVID-19 pandemic.
Keywords: Antibody; COVID-19; Lateral flow immunoassay; Orientation; SARS-CoV-2; Sensitive.